A PROMISING CORONAVIRUS vaccine candidate cleared a key hurdle this week, when Moderna Therapeutics entered phase two of clinical trials. The move signals that the company’s mRNA vaccine has passed its initial safety checks and has met an important milestone in bringing this drug closer to the public and commercial markets.
After almost five months of global deaths and economic shutdowns wrought by the COVID-19 pandemic, people are anxiously awaiting a glimmer of hope for a return to normal routines. This partly explains the recent frenzy over results from Moderna and its frontrunner candidate, which moved from the company’s lab in Cambridge, Massachusetts, to human trials in a record-setting 63 days.
Image Deleted Because Wiki Page Empty or Removed Image